Abivax SA (NASDAQ:ABVX) stock is up on Thursday, even as the company’s shares plunged following the release of trial data.

On Tuesday, the French biotech released data from its Phase 3 ABTECT maintenance trial evaluating obefazimod for ulcerative colitis.

The trial showed significant efficacy, with remission rates exceeding 50% for both doses tested, although concerns about reported cancer cases may weigh on investor sentiment following the trial results.

ABVX Catalyst: Phase 3 Obefazimod Data In Ulcerative Colitis

The Phase 3 trial enrolled 580 patients and demonstrated that both 25 mg and 50 mg doses of obefazimod met the FDA’s primary endpoint of clinical remission, achieving remission rates of 50.8% and 51.3%, respectively.

However, the reported cases of cancer during the study, including prostate and breast cancer, have raised concerns among investors, prompting analysts to caution that these ...